transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2022-14-2-184-194transplantologiya-656Research ArticleОБЗОРНЫЕ СТАТЬИ И ЛЕКЦИИREVIEW ARTICLES AND LECTURESДоступные способы повышения регенераторного потенциала пластического материала в неотложной травматологии. Часть 2. Использование аутологичного тромбоцитарного лизата человекаAvailable methods to enhance regenerative potential of plastic materials for bone defects replacement in orthopedics. Part 2. Use of autologous human platelet lysatehttps://orcid.org/0000-0001-8616-920XФайнА. М.FaynA. M.

Алексей Максимович Файн, д-р мед. наук, заведующий научным отделением неотложной травматологии опорно-двигательного аппарата; профессор кафедры травматологии, ортопедии и медицины катастроф

129090, Москва, Большая Сухаревская пл., д. 3127473, Москва, Делегатская ул., д. 20, стр. 1

Aleksey M. Fayn, Dr. Sci. (Med.), Head of the Scientific Department of Emergency Traumatology of the Musculoskeletal System; Professor of the Department of Traumatology, Orthopedics, and Disaster Medicine

3 Bolshaya Sukharevskaya Sq., Moscow 12909020 Bldg. 1 Delegatskaya St., Moscow 127473

FainAM@sklif.mos.ruhttps://orcid.org/0000-0003-4581-449XВазаА. Ю.VazaA. Yu.

Александр Юльевич Ваза, канд. мед. наук, ведущий научный сотрудник отделения неотложной травматологии опорно-двигательного аппарата

129090, Москва, Большая Сухаревская пл., д. 3

Aleksandr Yu. Vaza, Cand. Sci. (Med.), Leading Researcher, the Department of Emergency Traumatology of the Musculoskeletal System

3 Bolshaya Sukharevskaya Sq., Moscow 129090

VazaAU@sklif.mos.ruhttps://orcid.org/0000-0001-9932-1653ГнетецкийС. Ф.GnetetskiyS. F.

Сергей Феликсович Гнетецкий, д-р мед. наук, ведущий научный сотрудник отделения неотложной травматологии опорно-двигательного аппарата; доцент кафедры травматологии, ортопедии и медицины катастроф

129090, Москва, Большая Сухаревская пл., д. 3127473, Москва, Делегатская ул., д. 20, стр. 1

Sergey F. Gnetetskiy, Dr. Sci. (Med.), Leading Researcher, the Department of Emergency Traumatology of the Musculoskeletal System; Associate Professor of the Department of Traumatology, Orthopedics, and Disaster Medicine

3 Bolshaya Sukharevskaya Sq., Moscow 12909020 Bldg. 1 Delegatskaya St., Moscow 127473

GnetetskiySF@sklif.mos.ruhttps://orcid.org/0000-0003-3074-453XСкуратовскаяК. И.SkuratovskayaK. I.

Кристина Ивановна Скуратовская, младший научный сотрудник отделения неотложной травматологии опорно-двигательного аппарата

129090, Москва, Большая Сухаревская пл., д. 3

Kristina I. Skuratovskaya, Junior Researcher, the Department of Emergency Traumatology of the Musculoskeletal System

3 Bolshaya Sukharevskaya Sq., Moscow 129090

SkuratovskayaKI@sklif.mos.ruhttps://orcid.org/0000-0002-1183-3644БондаревВ. Б.BondarevV. B.

Василий Бриджевич Бондарев, научный сотрудник отделения неотложной травматологии опорно-двигательного аппарата

129090, Москва, Большая Сухаревская пл., д. 3

Vasiliy B. Bondarev, Researcher, the Department of Emergency Traumatology of the Musculoskeletal System

3 Bolshaya Sukharevskaya Sq., Moscow 129090

BondarevVB@sklif.mos.ruhttps://orcid.org/0000-0002-1509-7082БоголюбскийЮ. А.BogolyubskiyYu. A.

Юрий Андреевич Боголюбский, канд. мед. наук, научный сотрудник отделения неотложной травматологии опорно-двигательного аппарата

129090, Москва, Большая Сухаревская пл., д. 3

Yuriy A. Bogolyubskiy, Cand. Sci. (Med.), Researcher, the Department of Emergency Traumatology of the Musculoskeletal System

3 Bolshaya Sukharevskaya Sq., Moscow 129090

BogoljubskijUA@sklif.mos.ruhttps://orcid.org/0000-0002-2960-8736ТитовР. С.TitovR. S.

Роман Сергеевич Титов, канд. мед. наук, старший научный сотрудник отделения неотложной травматологии опорно-двигательного аппарата

129090, Москва, Большая Сухаревская пл., д. 3

Roman S. Titov, Cand. Sci. (Med.), Senior Researcher, the Department of Emergency Traumatology of the Musculoskeletal System

3 Bolshaya Sukharevskaya Sq., Moscow 129090

TitovRS@sklif.mos.ruhttps://orcid.org/0000-0001-9574-398XСергеевА. Ю.SergeevA. Yu.

Александр Юрьевич Сергеев, научный сотрудник отделения неотложной травматологии опорно-двигательного аппарата

129090, Москва, Большая Сухаревская пл., д. 3

Aleksandr Yu. Sergeev, Researcher, Department of Emergency Traumatology of the Musculoskeletal System

3 Bolshaya Sukharevskaya Sq., Moscow 129090

SergeevAY@sklif.mos.ruГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»; ФГБОУ ВО МГМСУ им. А.И. Евдокимова МЗ РФРоссияN.V. Sklifosovsky Research Institute for Emergency Medicine; A.I. Yevdokimov Moscow State University of Medicine and DentistryRussian FederationГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»РоссияN.V. Sklifosovsky Research Institute for Emergency MedicineRussian Federation202214062022142184194Copyright © Файн А.М., Ваза А.Ю., Гнетецкий С.Ф., Скуратовская К.И., Бондарев В.Б., Боголюбский Ю.А., Титов Р.С., Сергеев А.Ю., 20222022Файн А.М., Ваза А.Ю., Гнетецкий С.Ф., Скуратовская К.И., Бондарев В.Б., Боголюбский Ю.А., Титов Р.С., Сергеев А.Ю.Fayn A.M., Vaza A.Y., Gnetetskiy S.F., Skuratovskaya K.I., Bondarev V.B., Bogolyubskiy Y.A., Titov R.S., Sergeev A.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/656

В предыдущей статье было рассказано про применение богатой тромбоцитами плазмы. Одним из перспективных способов стимуляции процессов репарации и регенерации в тканях поврежденного органа при разных видах патологии является применение лизата богатой тромбоцитами плазмы. В данной части литературного обзора рассматривается механизм действия лизата богатой тромбоцитами плазмы, показания и противопоказания к его применению, описаны результаты лечения при использовании лизата богатой тромбоцитами плазмы для стимуляции остеогенеза. Благодаря технологии изготовления, предусматривающей удаление из плазмы всех клеточных компонентов, появляется возможность долговременного хранения полученного индивидуального трансплантата. Процедура изготовления тромбоцитарного лизата позволяет одномоментно выделять из клеток все ростовые факторы, так же происходит лизис тромбоцитов. Лизат тромбоконцентратов можно рассматривать как препарат, содержащий полноценный набор стимулирующих факторов роста. Под действием тромбоцитарного лизата происходит возобновление пролиферации латентных остеобластов, активация сигнальных путей ангиогенеза, стимуляция секреции факторов, ускоряющих ангиогенез, запускается дифференцировка остеобластов и образование костной ткани. Целью данной статьи является обобщение результатов лечения с использованием аутологичного тромбоцитарного лизата для улучшения регенераторного потенциала в травматологии. В заключительной статье мы рассмотрим способы применения аутологичного красного костного мозга.

In the previous article, we talked about the use of platelet-rich plasma. One of the promising ways to stimulate the processes of repair and regeneration in the tissues of the damaged organ in different types of pathology is the use of platelet-rich plasma lysate. This part of the literature review covers the mechanism of action of platelet-rich plasma lysate, indications and contraindications for its use, describes the results of treatment when platelet-rich plasma lysate is used to stimulate osteogenesis. The preparation technology provides for the removal of all cellular components from the plasma, so it becomes possible to store the obtained graft for a long time. The procedure for the preparation of platelet lysate allows the simultaneous isolation of all growth factors from the cells, since the platelet lysis occurs. Lysate of platelet concentrates can be considered as a preparation that contains a complete set of stimulating growth factors. Under the influence of the lysate, the proliferation of latent osteoblasts is resumed, the signaling pathways of angiogenesis are activated, the secretion of the factors accelerating angiogenesis is stimulated, the differentiation of osteoblasts and the formation of bone tissue are triggered. The aim of this article is to summarize the results of treatment using autologous platelet lysate to improve bone regenerative potential in orthopaedics. In a final article, we shall look at the ways to use autologous red bone marrow.

остеогенезложный суставтромбоцитарный лизаттравматологиякостная пластикакостный дефектангиогенезтромбоцитарные факторыbone regenerationpseudoarthrosisplatelet-rich plasmagrowth factorsbone graftinГосударственное бюджетное финансирование. Работа включена в научно-исследовательский план ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ».Financed from the State budget. The study has been included in the Research Plan of the N.V. Sklifosovsky Research Institute for Emergency Medicine.ReferencesNotodihardjo SC, Morimoto N, Kakudo N, Mitsui T, Le TM, Tabata Y, Kusumoto K. Comparison of the efficacy of cryopreserved human platelet lysate and refrigerated lyophilized human platelet lysate for wound healing. Regene Ther. 2019;10:1–9. PMID: 30525065 https://doi.org/10.1016/j.reth.2018.10.003Notodihardjo SC, Morimoto N, Kakudo N, Mitsui T, Le TM, Tabata Y, Kusumoto K. Comparison of the efficacy of cryopreserved human platelet lysate and refrigerated lyophilized human platelet lysate for wound healing. Regene Ther. 2019;10:1–9. PMID: 30525065 https://doi.org/10.1016/j.reth.2018.10.003Shih DTB, Burnouf T. Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. N Biotechnol. 2015;32(1):199–211. PMID: 24929129 https://doi.org/10.1016/j.nbt.2014.06.001Shih DTB, Burnouf T. Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. N Biotechnol. 2015;32(1):199–211. PMID: 24929129 https://doi.org/10.1016/j.nbt.2014.06.001Zimmermann R, Jakubietz R, Jakubietz M., Strasser E., Schlegel A, Wiltfang J, et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion. 2001;41(10):1217-1224. PMID: 11606819 https://doi.org/10.1046/j.1537-2995.2001.41101217.xZimmermann R, Jakubietz R, Jakubietz M., Strasser E., Schlegel A, Wiltfang J, et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion. 2001;41(10):1217-1224. PMID: 11606819 https://doi.org/10.1046/j.1537-2995.2001.41101217.xBonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43(3):245–251. PMID: 18820709 https://doi.org/10.1038/bmt.2008.316Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43(3):245–251. PMID: 18820709 https://doi.org/10.1038/bmt.2008.316Kaux JF, Le Goff C, Renouf J, Peters P, Lutteri L, Gothot A, et al Comparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS™ II and GPS™ III systems. Pathol Biol (Paris). 2011; 59(5):275–277. PMID: 21145177 https://doi.org/10.1016/j.patbio.2010.11.002Kaux JF, Le Goff C, Renouf J, Peters P, Lutteri L, Gothot A, et al Comparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS™ II and GPS™ III systems. Pathol Biol (Paris). 2011; 59(5):275–277. PMID: 21145177 https://doi.org/10.1016/j.patbio.2010.11.002Bieback K, Hecker A, Kocaömer A, Lannert H, Schallmoser K, Strunk D, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009;27(9):2331–2341. PMID: 19544413 https://doi.org/10.1002/stem.139Bieback K, Hecker A, Kocaömer A, Lannert H, Schallmoser K, Strunk D, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009;27(9):2331–2341. PMID: 19544413 https://doi.org/10.1002/stem.139Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials. 2010;31(2):270–278. PMID: 19783038 https://doi.org/10.1016/j.biomaterials.2009.09.043Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials. 2010;31(2):270–278. PMID: 19783038 https://doi.org/10.1016/j.biomaterials.2009.09.043Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, et al. Platelet lysates promote mesenchymal stem cellexpansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005;205(2):228–236. PMID: 15887229 https://doi.org/10.1002/jcp.20391Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, et al. Platelet lysates promote mesenchymal stem cellexpansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005;205(2):228–236. PMID: 15887229 https://doi.org/10.1002/jcp.20391Shanskii YD, Sergeeva NS, Sviridova IK, Kirakozov MS, Kirsanova VA, Akhmedova SA, et al. Human platelet lysate as a promising growth-stimulating additive for culturing of stem cells and other cell types. Bull Exp Biol Med. 2013;156(1):146–151. PMID: 24319712 https://doi.org/10.1007/s10517-013-2298-7Shanskii YD, Sergeeva NS, Sviridova IK, Kirakozov MS, Kirsanova VA, Akhmedova SA, et al. Human platelet lysate as a promising growth-stimulating additive for culturing of stem cells and other cell types. Bull Exp Biol Med. 2013;156(1):146–151. PMID: 24319712 https://doi.org/10.1007/s10517-013-2298-7Leotot J, Coquelin L, Bodivit G, Bierling P, Hernigou P, Rouard H, et al. Platelet lysate coating on scaffolds directly and in directly enhances cell migration, improving bone and blood vessel formation. Acta Biomater. 2013;9(5):6630-6640. PMID: 23403167 https://doi.org/10.1016/j.actbio.2013.02.003Leotot J, Coquelin L, Bodivit G, Bierling P, Hernigou P, Rouard H, et al. Platelet lysate coating on scaffolds directly and in directly enhances cell migration, improving bone and blood vessel formation. Acta Biomater. 2013;9(5):6630-6640. PMID: 23403167 https://doi.org/10.1016/j.actbio.2013.02.003Hemeda H, Kalz J, Walenda G, Lohmann M, Wagner W. Heparin concentration is critical for cell culture with human platelet lysate. Cytotherapy. 2013;15(9): 1174–1181. PMID: 23845186 https://doi.org/10.1016/j.jcyt.2013.05.006Hemeda H, Kalz J, Walenda G, Lohmann M, Wagner W. Heparin concentration is critical for cell culture with human platelet lysate. Cytotherapy. 2013;15(9): 1174–1181. PMID: 23845186 https://doi.org/10.1016/j.jcyt.2013.05.006Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE. Platelet lysates produced from expired platelet concen trates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One. 2013;8(7):e68984 PMID: 23874839 https://doi.org/10.1371/journal.pone.0068984Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE. Platelet lysates produced from expired platelet concen trates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One. 2013;8(7):e68984 PMID: 23874839 https://doi.org/10.1371/journal.pone.0068984Боровкова Н.В., Малыгина М.А., Макаров М.С., Пономарев И.Н., Сторожева М.В., Сахарова О.М. Цито киновый состав как определяющий фактор противовоспалительного и регенераторного действия препаратов на основе тромбоцитов. Пироговский форум травматологов-ортопедов. Москва: Медфорум; 2019. c. 97–98. URL: https://www.elibrary.ru/download/elibrary_41303918_10233132.pdf [Дата обращения 6 апреля 2022 г.].Borovkova NV, Malygina MA, Makarov MS, Ponomarev IN, Storozheva MV, Sakharova OM. Tsitokinovyy sostav kak opredelyayushchiy faktor protivovospalitel'nogo i regeneratornogo deystviya preparatov na osnove trombotsitov. Pirogovskiy forum travmatologov-ortopedov. Moscow: Medforum Publ.; 2019. p. 97–98. Available at: https://www.elibrary.ru/download/elibrary_41303918_10233132.pdf [Accessed April 6, 2022]. (In Russ.).Torreggiani E, Perut F, Roncuzzi L, Zini N, Baglìo SR, Baldini N. Exosomes: novel effectors of human platelet lysate activity. Eur Cell Mater. 2014;28:137–51. PMID: 25241964 https://doi.org/10.22203/ecm.v028a11Torreggiani E, Perut F, Roncuzzi L, Zini N, Baglìo SR, Baldini N. Exosomes: novel effectors of human platelet lysate activity. Eur Cell Mater. 2014;28:137–51. PMID: 25241964 https://doi.org/10.22203/ecm.v028a11Gresele PC, Fuster V, Vermylen J. (eds.) Platelets in thrombotic and non thrombotic disorders. Pathophysiology, pharmacology and therapeutics. Cambridge University Press; 2002. p. 25.Gresele PC, Fuster V, Vermylen J. (eds.) Platelets in thrombotic and non thrombotic disorders. Pathophysiology, pharmacology and therapeutics. Cambridge University Press; 2002. p. 25.Adelson E, Rheingold JJ, Cros by WH. The platelet as a sponge: a review. Blood. 1961;17(6):767–774. PMID: 13681458 https://doi.org/10.1182/blood.V17.6.767.767Adelson E, Rheingold JJ, Cros by WH. The platelet as a sponge: a review. Blood. 1961;17(6):767–774. PMID: 13681458 https://doi.org/10.1182/blood.V17.6.767.767Schallmoser K, Rohde E, Bartmann C, Obenauf AC, Reinisch A, Strunk D. Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells. Biomed Mater Eng. 2009;19(4-5):271–276. PMID: 20042793 https://doi.org/10.3233/BME-2009-0591Schallmoser K, Rohde E, Bartmann C, Obenauf AC, Reinisch A, Strunk D. Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells. Biomed Mater Eng. 2009;19(4-5):271–276. PMID: 20042793 https://doi.org/10.3233/BME-2009-0591Shomento SH, Wan C, Cao X, Faugere MC, Bouxsein ML, Clemens TL, et al. Hypoxia-inducible factors 1alpha and 2alpha exert both distinct and overlapping functions in long bone development. J Сell Biochem. 2010;109(1):196–204. PMID: 19899108 https://doi.org/10.1002/jcb.22396Shomento SH, Wan C, Cao X, Faugere MC, Bouxsein ML, Clemens TL, et al. Hypoxia-inducible factors 1alpha and 2alpha exert both distinct and overlapping functions in long bone development. J Сell Biochem. 2010;109(1):196–204. PMID: 19899108 https://doi.org/10.1002/jcb.22396Richard DE, Berra E, Pouysse gur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000;275(35):26765-26771. PMID: 10837481 https://doi.org/10.1074/jcb.M003325200Richard DE, Berra E, Pouysse gur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000;275(35):26765-26771. PMID: 10837481 https://doi.org/10.1074/jcb.M003325200Van Nguyen T, Cancedda R, Descalzi F. Platelet lysate activates quiescent cell proliferation and reprogramming in human articular cartilage: involvement of hypoxia inducible factor 1. J Tissue Eng Regen Med. 2018;12(3):1691–1703. PMID:29052350 https://doi.org/10.1002/term.2595Van Nguyen T, Cancedda R, Descalzi F. Platelet lysate activates quiescent cell proliferation and reprogramming in human articular cartilage: involvement of hypoxia inducible factor 1. J Tissue Eng Regen Med. 2018;12(3):1691–1703. PMID:29052350 https://doi.org/10.1002/term.2595Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Nat Acad Sci USA. 2008;105(2):686–691. PMID: 18184809 https://doi.org/10.1073/pnas.0708474105Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Nat Acad Sci USA. 2008;105(2):686–691. PMID: 18184809 https://doi.org/10.1073/pnas.0708474105Fekete N, Gadelorge M, Fürst D, Maurer C, Dausend J, Fleury- Cappellesso S, et al. Platelet lysate from whole bloodderived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy. 2012;14(5):540–554. https://doi.org/10.3109/14653249.2012.655420Fekete N, Gadelorge M, Fürst D, Maurer C, Dausend J, Fleury- Cappellesso S, et al. Platelet lysate from whole bloodderived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy. 2012;14(5):540–554. https://doi.org/10.3109/14653249.2012.655420Tomlinson RE, Silva MJ. HIF-1 α regulates bone formation after osteogenic mechanical loading. Bone. 2015;73:98–104. PMID: 25541207 https://doi.org/10.1016/j.bone.2014.12.015Tomlinson RE, Silva MJ. HIF-1 α regulates bone formation after osteogenic mechanical loading. Bone. 2015;73:98–104. PMID: 25541207 https://doi.org/10.1016/j.bone.2014.12.015Wu C, Rankin EB, Castellini L, Fernandez-Alcudia J, Lagory EL, Andersen R, et al. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev. 2015;29(8):817–831. PMID: 25846796 https://doi.org/10.1101/gad.255000.114Wu C, Rankin EB, Castellini L, Fernandez-Alcudia J, Lagory EL, Andersen R, et al. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev. 2015;29(8):817–831. PMID: 25846796 https://doi.org/10.1101/gad.255000.114Lee SY, Park KH, Yu HG, Kook E, Song WH, Lee G, et al. Controlling hypoxia-inducible factor-2α is critical for maintaining bone homeostasis in mice. Bone Res. 2019;7:1–14. PMID: 31098335 https://doi.org/10.1038/s41413-019-0054-yLee SY, Park KH, Yu HG, Kook E, Song WH, Lee G, et al. Controlling hypoxia-inducible factor-2α is critical for maintaining bone homeostasis in mice. Bone Res. 2019;7:1–14. PMID: 31098335 https://doi.org/10.1038/s41413-019-0054-yHu K, Olsen BR. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J Clin Invest. 2016;126(2):509–526. PMID: 26731472 https://doi.org/10.1172/JCI82585Hu K, Olsen BR. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J Clin Invest. 2016;126(2):509–526. PMID: 26731472 https://doi.org/10.1172/JCI82585Wan C, Shao J, Gilbert SR, Riddle RC, Long F, Johnson, et al. Role of HIF1alpha in skeletal development. Ann NY Acad Scie. 2010;1192:322–326. PMID: 20392254 https://doi.org/10.1111/j.1749-6632.2009.05238.xWan C, Shao J, Gilbert SR, Riddle RC, Long F, Johnson, et al. Role of HIF1alpha in skeletal development. Ann NY Acad Scie. 2010;1192:322–326. PMID: 20392254 https://doi.org/10.1111/j.1749-6632.2009.05238.xRiddle RC, Khatri R, Schipani E, Clemens TL. Role of hypoxia-inducible factor-1alpha in angiogenic-osteogenic coupling. J Mol Med. 2009;87(6):583–590. PMID: 19415227 https://doi.org/10.1007/s00109-009-0477-9Riddle RC, Khatri R, Schipani E, Clemens TL. Role of hypoxia-inducible factor-1alpha in angiogenic-osteogenic coupling. J Mol Med. 2009;87(6):583–590. PMID: 19415227 https://doi.org/10.1007/s00109-009-0477-9Romaldini A, Ulivi V, Nardini M, Mastrogiacomo M, Cancedda R, Des calzi F. Platelet lysate inhibits NF-κB activation and induces proliferation and an alert state in quiescent human umbilical vein endothelial cells retain ing their differentiation capability. Cells. 2019;8(4):331. PMID: 30970613 https://doi.org/10.3390/cells8040331Romaldini A, Ulivi V, Nardini M, Mastrogiacomo M, Cancedda R, Des calzi F. Platelet lysate inhibits NF-κB activation and induces proliferation and an alert state in quiescent human umbilical vein endothelial cells retain ing their differentiation capability. Cells. 2019;8(4):331. PMID: 30970613 https://doi.org/10.3390/cells8040331Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21):2468–2473. PMID: 10851045 https://doi.org/10.1038/sj.onc.1203476Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21):2468–2473. PMID: 10851045 https://doi.org/10.1038/sj.onc.1203476Levy DE, Darnell JE. Stats: Transcriptional control and biological impact. Nature reviews molecular cell biology. 2002;3(9):651–662. PMID: 12209125 https://doi.org/10.1038/nrm909Levy DE, Darnell JE. Stats: Transcriptional control and biological impact. Nature reviews molecular cell biology. 2002;3(9):651–662. PMID: 12209125 https://doi.org/10.1038/nrm909Darnell JE. STATs and gene regulation. Science. 1997;277(5332):1630–1635. PMID: 9287210 https://doi.org/10.1126/science.277.5332.1630Darnell JE. STATs and gene regulation. Science. 1997;277(5332):1630–1635. PMID: 9287210 https://doi.org/10.1126/science.277.5332.1630Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008;28(2):185–200. PMID: 17457812 https://doi.org/10.1002/med.20101Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008;28(2):185–200. PMID: 17457812 https://doi.org/10.1002/med.20101Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Eng J Med. 2007;357(16):1608-1619. PMID: 17881745 https://doi.org/10.1056/NEJMoa073687Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Eng J Med. 2007;357(16):1608-1619. PMID: 17881745 https://doi.org/10.1056/NEJMoa073687Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448(7157):1058–1062. PMID: 17676033 https://doi.org/10.1038/nature06096Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448(7157):1058–1062. PMID: 17676033 https://doi.org/10.1038/nature06096Zhou H, Newnum AB, Martin JR, Li P, Nelson MT, Moh A, et al. Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species. Bone. 2011;49(3):404–411. PMID: 21555004 https://doi.org/10.1016/j.bone.2011.04.020Zhou H, Newnum AB, Martin JR, Li P, Nelson MT, Moh A, et al. Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species. Bone. 2011;49(3):404–411. PMID: 21555004 https://doi.org/10.1016/j.bone.2011.04.020Yu X, Wan Q, Cheng G, Cheng X, Zhang J, Pathak JL, et al. CoCl2 , a mimic of hypoxia, enhances bone marrow mesenchymal stem cells migra tion and osteogenic differentiation via STAT3 signaling pathway. Cell Biol Int. 2018;42(10):1321–1329. PMID: 29908007 https://doi.org/10.1002/cbin.11017Yu X, Wan Q, Cheng G, Cheng X, Zhang J, Pathak JL, et al. CoCl2 , a mimic of hypoxia, enhances bone marrow mesenchymal stem cells migra tion and osteogenic differentiation via STAT3 signaling pathway. Cell Biol Int. 2018;42(10):1321–1329. PMID: 29908007 https://doi.org/10.1002/cbin.11017Yu X, Wan Q, Ye X, Cheng Y, Pathak JL, Li Z. Cellular hypoxia promotes osteogenic differentiation of mesenchymal stem cells and bone defect healing via STAT3 signaling. Cell Mol Biol let. 2019;24(1):1–17. PMID: 31827540 https://doi.org/10.1186/s11658-019-0191-8Yu X, Wan Q, Ye X, Cheng Y, Pathak JL, Li Z. Cellular hypoxia promotes osteogenic differentiation of mesenchymal stem cells and bone defect healing via STAT3 signaling. Cell Mol Biol let. 2019;24(1):1–17. PMID: 31827540 https://doi.org/10.1186/s11658-019-0191-8Yu X, Li Z, Wan Q, Cheng X, Zhang J, Pathak JL, et al. Inhibition of JAK2/STAT3 signaling suppresses bone marrow stromal cells proliferation and osteogenic differentiation and impairs bone defect healing. Biol Chem. 2018;399(11):1313–1323. PMID: 30044759 https://doi.org/10.1515/hsz-2018-0253Yu X, Li Z, Wan Q, Cheng X, Zhang J, Pathak JL, et al. Inhibition of JAK2/STAT3 signaling suppresses bone marrow stromal cells proliferation and osteogenic differentiation and impairs bone defect healing. Biol Chem. 2018;399(11):1313–1323. PMID: 30044759 https://doi.org/10.1515/hsz-2018-0253Jiang H, Tan X, Ju H, Su J, Yan W, Song X, et al. Autologous platelet lysates local injections for treatment of tibia non-union with breakage of the nickel clad: a case report. SpringerPlus. 2016;5(1):2013. PMID: 27933268 https://doi.org/10.1186/s40064-016-3683-2Jiang H, Tan X, Ju H, Su J, Yan W, Song X, et al. Autologous platelet lysates local injections for treatment of tibia non-union with breakage of the nickel clad: a case report. SpringerPlus. 2016;5(1):2013. PMID: 27933268 https://doi.org/10.1186/s40064-016-3683-2Боровкова Н.В., Малыгина М.А., Макаров М.С., Сахарова О.М., Пономарев И.Н. Способ лечения пациентов с переломом шейки плеча. Патент № 2681753 С1 Российская Федерация. Опубликовано 12.03.2019. Бюллетень № 8. URL: https://patenton.ru/patent/RU2681753C1.pdf [Дата обращения 6 апреля 2022 г.].Borovkova NV, Malygina MA, Makarov MS, Sakharova OM, Ponomarev IN. Method of treating patients with shoulder neck fracture. Patent № 2681753 С1 Russian Federation. Published March 12, 2019. Bull. № 8. Available at: https://patenton.ru/patent/RU2681753C1.pdf [Accessed April 6, 2022].Henschler R, Gabriel C, Schallmoser K, Burnouf T, Koh MBC. Human platelet lysate current standards and future developments. Transfusion. 2019;59(4):1407–1413. PMID:30741431 https://doi.org/10.1111/trf.15174Henschler R, Gabriel C, Schallmoser K, Burnouf T, Koh MBC. Human platelet lysate current standards and future developments. Transfusion. 2019;59(4):1407–1413. PMID:30741431 https://doi.org/10.1111/trf.15174Labibzadeh N, Emadedin M, Fazeli R, Mohseni F, Hosseini SE, Moghadassali R, et al. Mesenchymal stromal cells implantation in combination with platelet lysate product is safe for reconstruction of human long bone nonunion. Cell J. 2016;18(3):302–309. PMID: 27602311 https://doi.org/10.22074/cellj.2016.4557Labibzadeh N, Emadedin M, Fazeli R, Mohseni F, Hosseini SE, Moghadassali R, et al. Mesenchymal stromal cells implantation in combination with platelet lysate product is safe for reconstruction of human long bone nonunion. Cell J. 2016;18(3):302–309. PMID: 27602311 https://doi.org/10.22074/cellj.2016.4557Centeno CJ, Schultz JR, Cheever M. A case series of percutaneous treatment of non-union fractures with autolo gous, culture expanded, bone marrow derived, mesenchymal stem cells and platelet lysate. J Bioengineer Biomedical Sci. 2011;1(S 2):1–6. https://doi.org/10.4172/2155-9538.S2-007Centeno CJ, Schultz JR, Cheever M. A case series of percutaneous treatment of non-union fractures with autolo gous, culture expanded, bone marrow derived, mesenchymal stem cells and platelet lysate. J Bioengineer Biomedical Sci. 2011;1(S 2):1–6. https://doi.org/10.4172/2155-9538.S2-007

The authors declare that there are no conflicts of interest present.